Here’s a scene I suspect is playing out in a lot of exam rooms. A patient you haven’t seen in eight months comes in for something unrelated. She’s down 45 pounds. You ask how she’s paying for her semaglutide now that her insurance dropped it. She smiles: “Oh, I get it online.” Then you ask when she last had blood work. Silence. That silence is the problem.
According to the Massachusetts Health Policy Commission, commercially insured glucagon-like peptide-1 (GLP-1) use for weight loss dropped 52 percent this past year as insurers pulled coverage. Gallup estimates roughly 40 million Americans are taking a GLP-1 medication. Those patients didn’t all stop. Many moved to compounded or gray-market versions, paid cash, and quietly walked out of the system that used to keep an eye on them.
Insurers didn’t stop covering lab work. But when patients leave the insured pathway for their medication, the prescribing physician, the follow-up visits, and the lab orders tend to leave with it. The drug stays. The oversight goes.
And long-term GLP-1 use deserves oversight. These are good medications. They are not vitamins.
Real physician voices, twice a week
Free, and one click to unsubscribe.
The kidneys don’t like being thirsty
Nausea, vomiting, diarrhea, and a sudden disinterest in food and water are common, especially after a dose increase. String a few rough days together and you can get real dehydration, and with it acute kidney injury. Longer-term data actually suggest GLP-1 medications may protect the kidneys. The risk isn’t the drug slowly eroding kidney function. It’s the patient who spent a weekend barely drinking and never told anyone.
The gallbladder keeps score
Rapid weight loss is a classic setup for gallstones, and GLP-1 medications add to that risk. The liver and pancreas deserve attention too. Many patients with fatty liver improve on these drugs, which is great, but it makes a trend worth having. If numbers that were falling suddenly climb, something else may be going on. A patient who shrugs off right-sided abdominal pain as “just the shot” can end up in the ER with cholecystitis that was brewing for weeks.
Eating less means getting less
Appetite suppression is the point. But a patient living on crackers and coffee isn’t getting enough protein, iron, B12, folate, or vitamin D. The fallout shows up slowly: fatigue, thinning hair, tingling feet, anemia. Patients blame the medication or “getting older.” Often it’s simply not enough food.
Not all weight lost is fat
This is the one I most want people to understand. In some GLP-1 trials, roughly a quarter to nearly 40 percent of the weight lost came from lean mass. For a 35-year-old, that may be manageable. For a 68-year-old, it can mean sarcopenia: weaker legs, slower stairs, and a real chance of falling.
Bone follows the same path. Large, rapid weight loss is associated with increased bone turnover and declining bone density, especially at the hip. The drug itself doesn’t appear to be the main culprit. The drivers are the weight loss, less load on the skeleton, and too little protein, calcium, and vitamin D. Put sarcopenia and bone loss together in a postmenopausal woman and you have a fall waiting for a fracture.
The good news: Exercise helps. In one trial, patients who combined a GLP-1 medication with exercise preserved bone density better than those who lost weight through diet alone. Resistance training and adequate protein aren’t extras. They’re part of the treatment. For higher-risk patients, bone density testing is worth a conversation.
One quiet trap: Standard kidney function testing relies partly on muscle mass. Lose muscle, and the kidneys can look healthier on paper than they are.
Thyroid and blood sugar
GLP-1 medications carry a boxed warning about a rare thyroid cancer seen in rodents, and they’re off-limits for anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2). Someone buying from a website may never have been asked. Patients on thyroid replacement may also find their dose needs shift as the weight comes off.
Then there’s blood sugar. A patient with diabetes who’s still on insulin or a sulfonylurea, and who added a GLP-1 on their own, is set up for hypoglycemia. Nobody adjusted the other medications, because nobody knew.
Compounded products add their own wrinkle
The Food and Drug Administration (FDA) has reported overdoses tied to dosing errors with compounded GLP-1 products, often from confusion over units and syringes. Potency can vary. With no one guiding dose increases, some patients titrate by feel.
So what’s a patient on a budget supposed to do?
There’s no universal checklist. The right tests depend on age, other conditions, and other medications. But there are practical, affordable options:
- Talk to a primary care physician. Even if they don’t prescribe the GLP-1, they can decide what to check and how often. Tell them exactly what you’re taking and where you get it.
- Use cash-pay lab options. Many labs publish self-pay prices, community health centers offer sliding-scale care, and direct-to-consumer lab testing websites offer individual tests and pre-made panels at transparent prices.
Whatever the route, get the results in front of a clinician. A lab result sitting unread in an app isn’t monitoring. It’s a receipt.
A request to my colleagues
Ask every patient on a GLP-1 two questions: Where are you getting it? And who’s checking your labs?
Losing coverage shouldn’t mean losing oversight. The medication is working. Let’s make sure the patient is too.
Youmna DiStefano is a physician executive.
